Literature DB >> 21431989

Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis.

L Fox1, M R Kramer, I Haim, R Priess, A Metvachuk, D Shitrit.   

Abstract

Limited data exist about the clinical characteristics of Mycobacterium tuberculosis (TB) isolates with resistance to isoniazid (IZN). We describe the demographic and clinical characteristics and risk factor information for persons with IZN monoresistant (resistant to isoniazid) TB compared with drug-susceptible TB and multidrug-resistant (MDR) TB. From 2002 to 2009, 590 cases of TB were diagnosed. Of these, 44 (7.5%) developed MDR-TB and 38 (6.4%) had IZN monoresistant TB. Among the IZN monoresistant TB patients, more common demographic characteristics were former resident of the Soviet Union immigrant, smoker, and previous history of TB (p = 0.005, 0.025, and 0.005, respectively), while HIV, weight loss, and hemoptysis were less common (p = 0.005 for all parameters). The mean length of treatment was 24 ± 4 months for MDR-TB, 10 ± 3 months for IZN monoresistant TB cases, and 8 ± 2 months for all other TB cases. The directly observed therapy (DOT) rate was similar in all three groups. However, treatment failure, completion of TB treatment, and mortality were all similar in drug-susceptible TB and higher in MDR-TB. In multivariate analysis, only a history of previous TB (odds ratio [OR] 1.4; 95% confidence interval [CI]: 1.2-1.6) was significantly associated with IZN monoresistant TB. IZN monoresistant TB has distinct characteristics. However, the length of treatment and outcome are similar to drug-susceptible TB cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21431989     DOI: 10.1007/s10096-011-1167-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  9 in total

1.  National action plan to combat multidrug-resistant tuberculosis.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1992-06-19

2.  Trends in drug-resistant tuberculosis in the United States, 1993-1996.

Authors:  M Moore; I M Onorato; E McCray; K G Castro
Journal:  JAMA       Date:  1997-09-10       Impact factor: 56.272

3.  Prevention and control of tuberculosis in correctional and detention facilities: recommendations from CDC. Endorsed by the Advisory Council for the Elimination of Tuberculosis, the National Commission on Correctional Health Care, and the American Correctional Association.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2006-07-07

4.  Treatment of isoniazid-resistant tuberculosis in southeastern Texas.

Authors:  P Escalante; E A Graviss; D E Griffith; J M Musser; R J Awe
Journal:  Chest       Date:  2001-06       Impact factor: 9.410

5.  The scope and impact of treatment of latent tuberculosis infection in the United States and Canada.

Authors:  Timothy R Sterling; James Bethel; Stefan Goldberg; Paul Weinfurter; Lourdes Yun; C Robert Horsburgh
Journal:  Am J Respir Crit Care Med       Date:  2006-01-19       Impact factor: 21.405

Review 6.  Antitubercular isoniazid and drug resistance of Mycobacterium tuberculosis--a review.

Authors:  Thomas Scior; Iván Meneses Morales; Solón Javier Garcés Eisele; David Domeyer; Stefan Laufer
Journal:  Arch Pharm (Weinheim)       Date:  2002       Impact factor: 3.751

7.  Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003.

Authors:  Andrea J Hoopes; J Steve Kammerer; Theresa A Harrington; Kashef Ijaz; Lori R Armstrong
Journal:  Arch Intern Med       Date:  2008-10-13

8.  Isoniazid resistance among tuberculosis patients by birth cohort in Germany.

Authors:  M Forssbohm; R Loddenkemper; H L Rieder
Journal:  Int J Tuberc Lung Dis       Date:  2003-10       Impact factor: 2.373

9.  Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis.

Authors:  Adithya Cattamanchi; Raymund B Dantes; John Z Metcalfe; Leah G Jarlsberg; Jennifer Grinsdale; L Masae Kawamura; Dennis Osmond; Philip C Hopewell; Payam Nahid
Journal:  Clin Infect Dis       Date:  2009-01-15       Impact factor: 9.079

  9 in total
  13 in total

1.  Isoniazid Monoresistance and Rate of Culture Conversion among Patients in the State of Georgia with Confirmed Tuberculosis, 2009-2014.

Authors:  Argita D Salindri; Rose-Marie F Sales; Lauren DiMiceli; Marcos C Schechter; Russell R Kempker; Matthew J Magee
Journal:  Ann Am Thorac Soc       Date:  2018-03

2.  Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa.

Authors:  Y F van der Heijden; F Karim; G Mufamadi; L Zako; T Chinappa; B E Shepherd; F Maruri; M-Y S Moosa; T R Sterling; A S Pym
Journal:  Int J Tuberc Lung Dis       Date:  2017-06-01       Impact factor: 2.373

3.  The disconnect between a national tuberculosis drug resistance survey and treatment outcomes: a lost opportunity.

Authors:  E S Click; J Chirenda; S Kibias; H J Menzies; J E Oeltmann; C Sentle; T Muribe; T D Lere; R Makombe; S Bamrah; B K Moore; K P Cain
Journal:  Int J Tuberc Lung Dis       Date:  2014-11       Impact factor: 2.373

4.  Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis.

Authors:  Ying Xi; Wei Zhang; Rui-Jun Qiao; Jun Tang
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

5.  Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.

Authors:  Hyun Lee; Byeong-Ho Jeong; Hye Yun Park; Kyeongman Jeon; Hee Jae Huh; Nam Yong Lee; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

6.  Rapid Molecular Detection of Multidrug-Resistant Tuberculosis by PCR-Nucleic Acid Lateral Flow Immunoassay.

Authors:  Hatairat Kamphee; Angkana Chaiprasert; Therdsak Prammananan; Natpapas Wiriyachaiporn; Airin Kanchanatavee; Tararaj Dharakul
Journal:  PLoS One       Date:  2015-09-10       Impact factor: 3.240

7.  Isoniazid Mono-Resistant Tuberculosis: Impact on Treatment Outcome and Survival of Pulmonary Tuberculosis Patients in Southern Mexico 1995-2010.

Authors:  Renata Báez-Saldaña; Guadalupe Delgado-Sánchez; Lourdes García-García; Luis Pablo Cruz-Hervert; Marlene Montesinos-Castillo; Leticia Ferreyra-Reyes; Miriam Bobadilla-Del-Valle; Sergio Canizales-Quintero; Elizabeth Ferreira-Guerrero; Norma Téllez-Vázquez; Rogelio Montero-Campos; Mercedes Yanes-Lane; Norma Mongua-Rodriguez; Rosa Areli Martínez-Gamboa; José Sifuentes-Osornio; Alfredo Ponce-de-León
Journal:  PLoS One       Date:  2016-12-28       Impact factor: 3.240

Review 8.  Association between tobacco smoking and drug-resistant tuberculosis.

Authors:  Ming-Gui Wang; Wei-Wei Huang; Yu Wang; Yun-Xia Zhang; Miao-Miao Zhang; Shou-Quan Wu; Andrew J Sandford; Jian-Qing He
Journal:  Infect Drug Resist       Date:  2018-06-12       Impact factor: 4.003

9.  Risk Factors for Multidrug-Resistant Tuberculosis among Patients with Pulmonary Tuberculosis at the Central Chest Institute of Thailand.

Authors:  Charoen Chuchottaworn; Vipa Thanachartwet; Piamlarp Sangsayunh; Thu Zar Myint Than; Duangjai Sahassananda; Manoon Surabotsophon; Varunee Desakorn
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

10.  Determinants of multidrug-resistant tuberculosis in Henan province in China: a case control study.

Authors:  Chunxiao Zhang; Yongliang Wang; Guangcan Shi; Wei Han; Huayang Zhao; Huiqiang Zhang; Xiue Xi
Journal:  BMC Public Health       Date:  2016-01-16       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.